Male and female breast cancer - Differences in DNA ploidy, p21 and p53 expression reinforce the possibility of distinct pathways of oncogenesis

Pathobiology

Volumn 74, Issue 6, 2007, Pages 323-327

  André, Saudade ^a   Pinto, António E ^a   Laranjeira, Cátia ^a   Quaresma, Manuela ^a   Soares, Jorge ^a  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

Author keywords

Ki 67; Male female breast cancer; p21; p53; Ploidy; pRb

Indexed keywords

DNA; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANEUPLOIDY; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PLOIDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PLOIDIES; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 37249083149     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110025     Document Type: Article

References (30)

1. Muir D, Kanthan R, Kanthan SC: Male versus female breast cancers. A population-based comparative immunohistochemical analysis. Arch Pathol Lab Med 2003;127:36-41.
2. Giordano S: A review of the diagnosis and management of male breast cancer. Oncologist 2005;10:471-479.
3. Curigliano G, Colleoni M, Renne G, Mazzarol G, Gennari R, Peruzzotti G, de Braud E, Robertson C, Maiorano E, Veronesi P, Nole F, Mandala M, Ferretti G, Viale G, Goldhirsch A: Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. Ann Oncol 2002;13:895-902.
4. Weiss RH: p21Wafl/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003;4:425-429.
5. WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis. J Clin Pathol 2003;56:214-220.
6. waf1, and p53 in node negative invasive ductal breast carcinoma. Mol Pathol 2003;56:328-335.
7. Haupt Y, Robles AI, Prives C, Rotter V: Deconstruction of p53 functions and regulation. Oncogene 2002;21:8223-8231.
8. Fan Y, Borowsky AD, Weiss RH: An antisense oligodeoxynucleotide to p21 (Wafl/Cip1) causes apoptosis in human breast cancer cells. Mol Cancer Ther 2003;2:773-782.
9. Bearss DJ, Lee RJ, Troyer DA, Pestell RG, Windle JJ: Differential effects of p21 WAF1/CIP1 deficiency on MMTV-ras and MMTVmyc mammary tumor properties. Cancer Res 2002;62:2077-2084.
10. Chen X, Danes C, Lowe M, Herliczek TW, Keyomarsi K: Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells. J Natl Cancer Inst 2000;92:1403-1413.
11. Ceccarelli C, Santini D, Chieco P, Taffurelli M, Gamberini M, Pileri SA, Marrano D: Retinoblastoma (RB1) gene product expression in breast carcinoma. Correlation with Ki-67 growth fraction and biopathological profile. J Clin Pathol 1998;51:818-824.
12. Pinto AE, André S, Soares J: Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients. J Clin Pathol 1999;52:604-611.
13. Pich A, Margaria E, Ponti R, Geuna M: DNA ploidy and p53 expression correlate with survival and cell proliferative activity in male breast carcinoma. Hum Pathol 1996;27:676-682.
14. Tavassoli FA, Devilee P (eds): World Health Organization of Tumors. Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon, IARC Press, 2003.
15. American Joint Committee on Cancer: Breast;in Greene FL, Page DL, Fleming ID (eds): AJCC Cancer Staging Handbook, ed 6. New York, Springer, 2002.
16. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. 1. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
17. Hsu SM, Raine L, Fanger H: The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase techniques. Am J Clin Pathol 1981;75:816-821.
18. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA: Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983;31:1333-1335.
19. Jiang Z, Zacksenhaus E: Activation of retinoblastoma protein in mammary gland leads to ductal growth suppression, precocious differentiation, and adenocarcinoma. J Cell Biol 2002;156:185-198.
20. Wick MR, Sayadi H, Ritter JH, Hill DA, Reddy VB, Gattuso P: Low-stage carcinoma of the male breast. A histologic, immunohistochemical, and flow cytometric comparison with localized female breast carcinoma. Am J Clin Pathol 1999;111:59-69.
21. Burga AM, Fadare O, Lininger RA, Tavassoli FA: Invasive carcinomas of the male breast: a morphologic study of the distribution of histologic subtypes and metastatic patterns in 778 cases. Virchows Arch 2006;449:507-512.
22. André S, Fonseca I, Pinto AE, Cardoso P, Pereira T, Soares J: Male breast cancer. A reappraisal of clinical and biologic indicators of prognosis. Acta Oncol 2001;40:472-478.
23. Ioachim EE, Malamou-Mitsi V, Kamina SA, Goussia AC, Agnantis NJ: Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices. Anticancer Res 2000;20:4221-4226.
24. Domagala W, Welcker M, Chosia M, Karbowniczek M, Harezga B, Bartkova J, Bartek J, Osborn M: p21/WAF1/Cip1 expression in invasive ductal breast carcinoma: relationship to p53, proliferation rate, and survival at 5 years. Virchows Arch 2001;439:132-140.
25. Mourao Netto M, Logullo AF, Nonogaki S, Brentani RR, Brentani MM: Expression of cerbB-2, p53 and c-myc proteins in male breast carcinoma: comparison with traditional prognostic factors and survival. Braz J Med Biol Res 2001;34:887-894.
26. Wang-Rodrigues J, Cross K, Gallagher S, Djahanban M, Amstrong JM, Wiedner N, Shapiro DH: Male breast carcinoma: Correlation of ER, PR, Ki-67, Her2-neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol 2002;15:853-861.
27. O'Hanlon DM, Kiely M, MacConmara M, Al-Azzawit R, Connolly Y, Jeffers M, Keane FBV: An immunohistochemical study of p21 and p53 expression in primary node-positive breast carcinoma. Eur J Surg Pathol 2002;26:103-107.
28. waf correlates with DNA replication but not with prognosis in invasive breast cancer. J Clin Pathol 2001;54:866-870.
29. Michels JJ, Duigou F, Marnay J, Henry-Amar M, Delozier T, Denoux Y, Chasle J: Flow cytometry and quantitative immunohistochemical study of cell cycle regulation proteins in invasive breast carcinoma. Prognostic significance. Cancer 2003;97:1376-1386.
30. Pinto AE, André S, Laranjeira C, Soares J: Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer. Pathology 2005;37:45-50.